Hutnik to support the company in its continued efforts to develop N, N-dimethyltryptamine (DMT) as a potential treatment for glaucoma
PharmaDrug Inc has announced the appointment of Dr. Cindy Hutnik to the Company’s Scientific and Clinical Advisory Board.
PharmaDrug said Hutnik will help the company in its continued efforts to develop N, N-dimethyltryptamine (DMT) and other tryptamine analogues as a potential treatment for glaucoma.
“Dr. Hutnik is a highly regarded leader in the field of glaucoma, and she brings invaluable advice and invaluable clinical trial experience having served as a principal investigator on various clinical trials in the field of glaucoma,” said Daniel Cohen, CEO of PharmaDrug, in a statement.
Dr. Hutnik, who is the current President of the Canadian Glaucoma Society, is also a Full Professor in the Departments of Ophthalmology and Pathology at the Schulich School of Medicine and Dentistry.
READ: PharmaDrug aims to start clinical studies using cepharanthin for coronavirus in second half of next year
The company also noted that, as part of an ongoing sponsored research agreement with the Terasaki Institute of Biomedical Innovation, it has initiated in vitro studies to assess the impact (cytotoxicity, potency and duration of activity) of its two candidate molecules on specific cell types known to regulate pressure imbalance in the eyes of patients with glaucoma.
In vivo studies are expected to begin in the second trimester with an emphasis on assessing safety and efficacy when applied as topical eye drops in animal models of glaucoma.
These studies will then be followed by the development and testing of a medical device specially designed to provide sustained, local and sub-psychotropic levels of the developmental candidate to patients with glaucoma.
PharmaDrug is focused on advancing the clinical development of an improved oral formulation of cepharanthin (PD-001) to treat rare cancers and COVID-19.
Contact Sean at [email protected]